• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature

    2022-12-09 02:52:20ChaLenLeeSpringHolterAyeletBorgidaAnnaDoddStephanieRamotarRobertGrantKristyWassonElenaElimovaRaymondJangMalcolmMooreTaeKyoungKimKoroshKhaliliCarolAnneMoultonStevenGallingerGrainneOKaneJenniferKnox
    World Journal of Gastroenterology 2022年45期

    Cha Len Lee, Spring Holter, Ayelet Borgida, Anna Dodd, Stephanie Ramotar,Robert Grant, Kristy Wasson,Elena Elimova, Raymond W Jang, Malcolm Moore, Tae Kyoung Kim, Korosh Khalili, Carol-Anne Moulton,Steven Gallinger,Grainne M OKane, Jennifer J Knox

    Abstract

    Key Words: Pancreatic acinar carcinoma; BRCA; Polyadenosine diphosphate-ribose polymerase inhibitor;Case report

    INTRODUCTION

    Pancreatic acinar cell carcinoma (PACC) is a rare subtype of pancreatic cancer, accounting for 1%-2% of exocrine pancreatic neoplasms[1]. While there is some clinical and genotype difference, patients with PACC and pancreatic ductal adenocarcinoma (PDAC) are often treated as one disease entity. Evolving data has increased our understanding of this rare tumor’s biology, treatment, and prognosis. Due to the disease’s rarity, most data about PACC are limited to reviews, case reports, and case series. The tumor biology of PACC is not well characterized due to the lack of tissue availability for large-scale molecular analysis. Intriguingly, data obtained in recent years have indicated that PACC has a distinctive mutational landscape[2-4]. There is increasing interest in this area, particularly regarding the homologous repair deficiency (HRD) signature in PACC. Chmieleckiet al[2] reported up to 45%deficiency of the DNA damage repair (DDR) pathway genes in the study population. Oncogenic therapeutic targets includingRAF1rearrangements and mismatch repair genes have proven elusive in a significant proportion of PACCs, and lack of tumor profiling probably contributes to low reporting[3,4].

    Here, we present a PACC case to emphasize the clinical application of genomic profiling in the context of precision medicine for better patient outcomes. Although this patient was very unwell at the presentation, raising the question of suitability for modified FOLFIRINOX (mFFX), the knowledge of theBRCA2likely pathogenic variant (LPV) as predictive for mFFX sensitivity guided our decision to use this regime. In the case series section, we describe the clinical characteristics, therapeutic outcomes, and mutational signatures of additional 10 patients with PACC treated in our center. As proof of concept, we describe the immediate clinical impact for the patients with distinct genomic alterations that have been associated with sensitivity to specific chemotherapeutic or targeted agents.

    CASE PRESENTATION

    Chief complaints

    The patient was a 70 male smoker with recurrent lower limb joint pain and was generally unwell for the previous year.

    History of present illness

    He presented to a rheumatology service with joint pain, which was diagnosed as gout and treated with short courses of prednisolone; however, during the steroid treatment, he also experienced central abdominal discomfort, reduced appetite, and 10 kg weight loss. He had progressive lower joint pain with tender, warm skin nodules, which restricted mobility.

    History of past illness

    He had encephalitis and asthma as a child.

    Personal and family history

    He had a history of transitional cell carcinoma of the renal pelvis at age 46 for which he underwent a left total nephrectomy and a non-small cell lung adenocarcinoma at age 51, which was treated by lung resection. His mother died of ovarian cancer at age 72.

    Physical examination

    Physical examination revealed a cachectic man with a palpable liver edge and ill-defined widespread erythematous subcutaneous nodules on bilateral lower limbs (Figure 1A). Eastern Cooperative Oncology Group performance status (PS) was 2.

    Laboratory examinations

    Initial blood tests demonstrated lipase > 6000 U/dL, elevated transaminases [alanine aminotransferase(ALT) 68 U/L and aspartate aminotransferase 58 U/L], total bilirubin 6 μmol/L, albumin 28 g/L and creatinine 120 μmol/L (estimated glomerular filtration rate 52 mL/min). Tumor markers were: Normal carbohydrate antigen 19-9 (CA19-9) 28 kU/L and raised alpha-fetoprotein 58 μg/L.

    Imaging examinations

    Initial computed tomography (CT) imaging showed a bulky pancreatic tumor measuring over 16 cm and multiple liver metastases. The largest liver lesion measured over 8 cm (Figure 2A). There was an illdefined area of sclerosis in the right ischium which was suspicious of metastasis. Whole-body bone scintigraphy detected mild non-specific increased activity in the right ischium corresponding to the area of sclerosis but no significant bony abnormality. CT chest showed no evidence of thoracic metastases.

    FURTHER DIAGNOSTIC WORK-UP

    The patient underwent a liver biopsy that confirmed a poorly differentiated carcinoma staining positive for keratin 7, CAM5.2, claudin 4, glypican 3, and A1AT. Negative markers included keratin 20, arginase 1, hepPar1, synaptophysin, chromogranin, CD56, and TTF1. The tumor was mismatch repair proficient.An additional skin biopsy of one of the subcutaneous nodules confirmed pancreatic lobular panniculitis.Germline testing identified aBRCA2LPV (c.4356delinsCA, p. Gln1452Hisfs*8).

    CASE SERIES

    Population and clinical data

    We treated 11 PACC patients between August 2014 and July 2021 at Princess Margaret Cancer Centre(PMCC), Toronto. These comprised 6 (55%) pure and 5 (45%) mixed PACC. Approximately 2000 pancreatic carcinoma patients were managed at PMCC during this period. The median age at diagnosis of the PACC patients was 65 years (range 57-74) and all were male. At diagnosis, 2 (18%) were resectable, 2 (18%) locally advanced, and 7 (64%) metastatic. The full demographic features of all patients are summarized in Table 1.

    Four (36%) patients had curative-intent surgery. Three of them developed systemic relapse and received subsequent treatment with palliative chemotherapy. All seven metastatic patients had chemotherapy. Altogether, ten patients received palliative chemotherapy: mFFX (6), Gemcitabine plus Nab-paclitaxel (GnP) (3), and Gemcitabine (1).

    The median time to progression from the date of surgery to the first systemic relapse for the resected patients was 10.5 mo (1.5-10.6). After a follow-up period of 20.4 mo, 6 (55%) patients had died of the disease while five are still alive. The median overall survival (OS) of the cohort was 20.4 mo (range 4.6-36.0) but this variable is temporally immature. The median OS of the four resected patients was 30.3 mo(28.2-36.0).

    Genomic data

    Eligibility for germline genetic testing in Ontario has evolved with the advent of next-generation sequencing, newly identified genes, and the association of established genes with different cancer types.In April 2021, Ontario Health expanded the availability of germline testing to all individuals with pancreatic cancer regardless of age or family history[5]. Before this, germline testing for individuals with pancreatic cancer was based on personal and family history as well as the age of onset. The gene(s)or multi-gene panels performed for patients are based on the individuals’ personal and family history at the time of the initial genetic counseling.

    Table 1 Clinicohistopathologic features of the pancreatic acinar cell carcinoma patients in this dataset (n = 11)

    Seven patients in our case series had clinical germline testing. Four patients did not have germline testing, as they did not meet eligibility criteria based on family history at the time of their diagnosis.Germline PV/LPV was identified in four patients [2BRCA2(18%),1ATM(9%), 1CDKN2A(9%)]. Two(18%) patients had somatic testing with whole-genome sequencing and RNA sequencing as part of clinical trial participation. Identified somatic variants were SND1-BRAFfusion in one patient andKRAS,SMAD4,CDKN2A,ATM,TP53,TGFBR2, andKDM6Ain another patient.

    In terms of actionability, we identified two patients withBRCA2PV/LPV (18%) and oneSND1-BRAFfusion (9%). The first patient carrying a germlineBRCA2LPV is described in this case report. The second patient carrying a germlineBRCA2PV had advanced acinar neuroendocrine carcinoma. Briefly,he was commenced on a combination of 5 FU and Oxaliplatin with a dose reduction (30%) due to comorbidities. Despite this, the evaluation CT scan following 8 cycles of chemotherapy showed a partial response of the primary tumor (63% smaller than baseline) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. He continued additional 4 cycles with further tumor regression, followed by resection. The tumor was pathologic near complete treatment response.

    The patient harboring anSND1-BRAFfusion was commenced on first line GnP. The evaluation CT scans following 6 cycles of chemotherapy showed a significant partial response (55% decrease than baseline) of the primary tumor and lymph nodes as per RECIST1.1. After 16 cycles of GnP, he developed progressive disease and was switched to single-agent Cobimetinib as part of clinical trial participation.Molecular profiling was negative for other key driver mutationsKRAS, TP53, CDKN2A, SMAD4, andBRCAin this patient. Full mutational profiles of the patients and treatment history are outlined in Table 2.

    Table 2 Germline and somatic molecular profiles of the pancreatic ductal adenocarcinoma patients in this study

    TTP: Time to progression; OS: Overall survival; MMR IHC: Mismatch repair immunohistochemistry; mFFX: Modified FOLFIRINOX; GnP: Gemcitabine with Nab-paclitaxel; BSC: Best supportive care; PD: Progressive disease; DOD:Dead of disease; SD: Stable disease; PR: Partial response; AWD: Alive with the disease; WGS: Whole genome sequencing; RNA seq: RNA sequencing; PDAC: Pancreatic ductal adenocarcinoma; NSCLA: Non-small cell lung adenocarcinoma.

    FINAL DIAGNOSIS

    These findings were compatible with PACC with panniculitis, hepatic metastases, and indeterminate bony involvement. Histology revealed no concurrent existence of ductal adenocarcinoma, neuroendocrine or mixed tumor of the pancreas.

    TREATMENT

    The initial plan was to treat the patient with GnP in consideration of his poor PS. However, this decision was changed to the mFFX regimen following the documentation of the germlineBRCA2LPV. mFFX was administered every 2-wk with an additional 20% dose reduction of Oxaliplatin and Irinotecan(Oxaliplatin 65 mg/m2, Irinotecan 120 mg/m2, Fluorouracil 4200 mg/m2and Folinic acid 400 mg/m2).The chemotherapy calculations were based on a body surface area of 1.77 m2.

    Figure 1 Panniculitis is a skin manifestation that can be detected in up to 45% of patients before the recognition of pancreatic disease. A:The widespread ill-defined erythematous tender skin nodules and/or plaques that develop on the shins and around the ankles of our patient as the initial clinical presentation; B: Complete resolution of the panniculitis in our patient after 4 cycles of modified FOLFIRINOX, suggestive of early clinical response.

    Figure 2 Comparison of serial computed tomography images of our patient during chemotherapy. A: Initial axial post-contrast computed tomography (CT) scan shows a large heterogeneous solid mass in the pancreatic tail (short arrows) and a hypoattenuating metastatic liver mass (long arrow); B:Post-chemotherapy axial CT scan performed after 11 cycles of chemotherapy demonstrates marked interval reduction in the size of the pancreatic mass (arrows) and metastatic liver mass (not visible in this image).

    OUTCOME AND FOLLOW-UP

    After the first cycle of mFFX, the patient was hospitalized due to fever, confusion, and worsening polyarthritis. A full septic screen revealed no clear infectious etiology. CT brain showed no brain abnormality. X-rays of several joint areas including sacroiliac joints showed no radiographic evidence of osteomyelitis or septic arthritis. A left knee joint aspiration revealed an inflammatory synovial fluid with elevated white blood cell count, but no growth of infectious organisms and negative for crystal arthropathy. Rheumatoid factor and anti-cyclic citrullinated peptide levels were negative. The rheumatology team believed the patient’s inflammatory seronegative arthritis was paraneoplastic in nature. The patient also displayed clinical adverse events consistent with steroid-induced psychosis, due to the concurrent prednisolone and dexamethasone use. He was started on Naproxen with a tapering dose of prednisolone (from 15 mg daily). His condition improved within a week time and chemotherapy was resumed. Two months after starting mFFX, CT evaluation (post 4 cycles of chemotherapy)showed a 56% partial response based on RECIST1.1. The patient had a marked improvement in symptomatology and panniculitis (Figure 1B). His PS also improved to 0. He continued to tolerate mFFX with grade 1 peripheral sensory neuropathy of hands and feet. Another CT (post 8 cycles of chemotherapy)showed further tumor shrinkage in the primary tumor and hepatic metastases. The sclerotic bone lesion was unchanged in the interval. As the patient was getting a deepening partial response and tolerating mFFX, the chemotherapy was repeated for a total of 11 cycles. A CT imaging at that time point showed further tumor regression in the pancreatic tumor and the hepatic metastases, totaling a 70% decrease from baseline (Figure 2B). The biochemical response was also seen with a CA19-9 level of 17 kU/L.

    After 11 cycles of mFFX, we decided to stop chemotherapy due to the accumulative neurotoxicity.Considering the germlineBRCA2LPV, we elected a therapeutic switch to Olaparib, a polyadenosine diphosphate-ribose polymerase inhibitor (PARPi), as maintenance therapy. He was started on Olaparib 150 mg twice daily dosing that was adjusted for his renal function. At the time of this writing, the patient experienced disease stability for 5 mo with Olaparib, which is ongoing. He tolerates Olaparib with grade 1 fatigue but has no major side effects. He is on monthly follow-ups.

    DISCUSSION

    PACC typically presents in the younger population with a median age of 62 years old. It is more frequent in males, with a male-to-female ratio of 2.3:1[6-8]. The majority (50%-60%) present at an advanced stage, with a median tumor size of 7 cm, and lesions smaller than 2 cm are rarely detected[6-10]. Some cases present with mixed differentiation including mixed acinar-ductal and mixed acinarneuroendocrine subtypes. As the tumor is predominantly found in the tail of the pancreas, patients do not usually present with biliary obstruction, and elevation of CA19-9 is not typically seen[3,11].However, there have been reports of elevated alpha-fetoprotein in younger patients[7,8]. In extreme cases, up to 10%, of patients have lipase hypersecretion which leads to systemic fat necrosis with eosinophilia, erythematous subcutaneous nodules, and polyarthralgia[6,7,9,10]. This paraneoplastic syndrome,also known as Schmid’s triad, is often associated with a poor prognosis[12-15]. The prognosis of PACC is slightly better than that for PDAC[6]. In comparison, 5-year OS for PACC was 42.8%vsPDAC 3.8%[16]. In this study, we analyzed the full clinical characteristics, therapeutic outcomes, and mutational signatures of 11 patients with PACC treated at our center. Based on our analysis, the median OS across all stages is 20.4 mo and 30.3 mo among the resected patients.

    Available literature suggests that over one-third of PACC patients harbor potentially druggable alterations such asBRCA2, PALB2, ATM,BRAF,andJAK1[17]. We observed only one PACC with somaticKRASmutation (9%). This result may be limited by the incomplete somatic testing rate in this study. In distinction to PDAC which is associated withKRASdriver mutations in more than 93% of cases,KRASmutations occur at a much lower prevalence in the acinar/mixed neuroendocrine tumor(9%)[18-21]. While it is difficult to generalize as pancreatic carcinoma is a complex heterogeneous disease, a strong argument can be made that the lack of mutatedKRASidentifies a cohort rich in targetable alterations including fusions, and should have access to integrative germline and somatic sequencing[22].

    Multiple studies including a large series reported by Chmieleckiet al[2] involving 44 PACCs reported a 45% deficiency of DDR pathway genes[3,4,23]. These are inclusive of deficiencies in theBRCApathway and mismatch repair. Combined results suggested that approximately 23% of PACCs are enriched with fusion rearrangements involvingBRAForRAF1genes[2,19]. It appears that PACC subgroups that are lackingRAF1rearrangements (i.e.,fusion-negative tumors) were significantly enriched for deficiency in HRD, and both tumor types are mutually exclusive[2]. Conceptually, these“fusion-negative” tumors can serve as a beneficial demarcation in over two-thirds of PACC patients who may be candidates for platinum-based chemotherapy. PACC withBRCA1/2variants have greater sensitivity to platinum-based chemotherapy and demonstrate significantly better OS than when treated with non-platinum agents[24]. Platinum chemotherapy drugs exert their cytotoxic effect by binding directly to DNA, causing crosslinking of DNA strands and thereby inducing DNA double-strand breaks, which also are ineffectively repaired in cells lacking functioningBRCA1/2. Both the patients in our case series with germlineBRCA2PV/LPV had substantial radiographic regression despite dose reduced Oxaliplatin. Although our patient described in the case report was very unwell with poor PS at presentation, raising the question of suitability for mFFX, the knowledge of theBRCA2LPV as predictive for platinum sensitivity guided our decision to use this regime and resulted in his improved outcome. The other patient was successfully downsized to enable the Whipple procedure for curative intent. Notably, we identified one patient withSND1-BRAFkinase fusion in our case series. Germline and somatic testing were negative forBRCA1orBRCA2in this patient. This particular variant fusion joinsSND1exons 1-10 withBRAFexons 11-18 and maintains the reading frame. It is worth noting that this particular configuration is the most prevalent gene fusion described in melanoma, thyroid, and lung cancers. It has also been reported in PACC[2]. This novel fusion is potentially targetable with MEK inhibitors, such as Trametinib and Cobimetinib[2,25].

    Germline testing and tumor sequencing results are invaluable in identifying PACC patients for treatment regime determination and predictive biomarkers for investigational targeted therapies[14,22,23,26,27]. Newly diagnosed patients with PACC should undergo germline genetic testing and somatic profiling where appropriate, given the high frequency of pathogenic germlineBRCAalterations in PACC. This should be made available to patients regardless of clinical presentation, the pattern of metastases, and pre-existing co-morbidities. This is also consistent with NCCN American Society of Clinical Oncology guidelines which recommend all PDAC patients have upfront germline testing as part of the evolving precision strategy and screening strategies[28]. Similar to numerous studies, our patients with pathogenicBRCA1/2variants have an increased risk of pancreatic, ovarian, breast, and other cancers (Table 2). The lifetime risk for pancreatic cancer inBRCA1andBRCA2mutant carriers is 1% and 4.9%, respectively[29,30]. Unlike breast and ovarian cancers, germlineBRCA1/2mutations alone do not pose a significant risk of pancreatic cancers. Recent literature review showsBRCA2confer to 5%-17% of familial pancreatic cancers (FPC) andBRCA1is not as highly prevalent[31-34]. Studies show that germline susceptibility gene mutations were not found in 80% of pancreatic cancer individuals with strong family history[31,35]. Therefore, comprehensive genome sequencing is needed to identify new possible deleterious genes associated with FPC.

    There are no current clinical practice algorithms for PACC, and it is treated in the same way as PDAC. Although FOLFIRINOX represents the standard treatment with the highest efficacy in PDAC, it is not well studied in PACC[36]. Since 2010, there is a recognized OS benefit to platinum-based agents compared to Gemcitabine or Capecitabine-based regimens, and current therapeutic approaches of metastatic PACCs utilize more FOLFOX or FOLFIRINOX. Furukawaet al[37] described a PACC patient with aBRCA2PV who received Cisplatin after a recurrence of liver metastasis and had a complete remission of the recurring tumor. Ploquinet al[38] reported a PACC patient with aBRCA2PV who experienced a 14-year complete remission following nine cycles of GEMOX, without surgical intervention. Therefore, Cisplatin and GEMOX may be alternatives in patients harboring deficiencies in DDR genes who are unfit for FOLFIRINOX.

    Due to accumulative neurotoxicity after 11 cycles of mFFX, our patient decided to stop systemic chemotherapy completely and de-escalated to Olaparib as a maintenance approach. The use of PARPi in PACC patients with germlineBRCA1orBRCA2PV/LPV is anecdotal[2,23,26]. Furthermore, the updated analysis of the POLO trial showed a lack of OS benefit and quality of life improvement in their Olaparib-treated patients compared to the placebo arm[39]. Despite the aforementioned, we believe that metastatic PACC patients with confirmed HRD phenotype and demonstrated strictly defined platinum sensitivity that involved exceptional response after 16 wk of chemotherapy should be considered for the benefit of PARPi, as the case described.

    Like PDAC, surgery offers the best treatment approach for improved long-term survival[11,16,40].The combination of surgical approach and perioperative chemotherapy in PACC is mainly adapted from the PDAC practice[40-42]. As mentioned, our patient with metastatic germlineBRCA2PV had remarkable tumor downstaging following mFFX, underwent curative surgery, and achieved a pathologic near complete treatment response. Optimizing treatment approaches from this standpoint,with growing access to germline and somatic profiling, should also be further explored in PACC.

    CONCLUSION

    Although it is a rare disease, it is important to identify both common and rare actionable variants in PACCs. In PACC patients withBRCAvariants, the maintenance treatment of PARPi after effective platinum-based chemotherapy should be explored further. Surgical resection may provide the chance of cure after induction chemotherapy in very well-selected patients, particularly in patients withBRCAvariants. Further large-scale studies are required to verify these therapeutic strategies for PACC patients.

    ACKNOWLEDGEMENTS

    We acknowledged Dr. Thiago Muniz’s contribution to reviewing this manuscript for grammar and syntax.

    FOOTNOTES

    Author contributions:Lee CL contributed to the data investigation, writing, and editing of the original draft; Holter S participated in the genomics data curation and revision of the final manuscript; Borgida A, Dodd A and Ramotar S involved in the data acquisition and curation; Kim TY and Khalili K participated in the radiological investigation;Grant R, Elimova E, Wasson K, Jang RW, Moore M, and Moulton CA read and approved the final manuscript;Gallinger S and O’Kane GM reviewed and edited the manuscript; Knox JJ supervised the project and final manuscript revision.

    Informed consent statement:Informed consent is obtained from all participants. Written informed consent is obtained from the patient to publish the case report and accompanying images.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    CARE Checklist (2016) statement:The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:Canada

    ORCID number:Cha Len Lee 0000-0002-3919-7539.

    S-Editor:Wang JJ

    L-Editor:A

    P-Editor:Wang JJ

    性少妇av在线| 国产精品爽爽va在线观看网站 | 日本wwww免费看| 人人妻人人爽人人添夜夜欢视频| avwww免费| 男女高潮啪啪啪动态图| 欧美日韩福利视频一区二区| 亚洲男人天堂网一区| 免费日韩欧美在线观看| 欧美日韩一级在线毛片| 成人av一区二区三区在线看| 久久性视频一级片| 日韩欧美三级三区| 曰老女人黄片| 97人妻天天添夜夜摸| 精品人妻1区二区| 国产免费av片在线观看野外av| 亚洲精品一二三| 亚洲欧美一区二区三区黑人| 热99re8久久精品国产| 久久热在线av| 999久久久精品免费观看国产| 国产真人三级小视频在线观看| 亚洲精品美女久久av网站| 午夜福利在线观看吧| 很黄的视频免费| 看免费av毛片| 欧美一区二区精品小视频在线| 日本欧美视频一区| 亚洲av第一区精品v没综合| 日本wwww免费看| 免费在线观看日本一区| 超碰97精品在线观看| 国产欧美日韩一区二区三| 性色av乱码一区二区三区2| bbb黄色大片| 黄色怎么调成土黄色| 欧美精品亚洲一区二区| 国产真人三级小视频在线观看| 欧美日本中文国产一区发布| 麻豆国产av国片精品| 色尼玛亚洲综合影院| 国产亚洲精品一区二区www| 国产精品综合久久久久久久免费 | 波多野结衣av一区二区av| 国产精品九九99| 高清毛片免费观看视频网站 | 一进一出抽搐gif免费好疼 | 国产伦一二天堂av在线观看| 亚洲国产毛片av蜜桃av| 亚洲国产精品一区二区三区在线| 久久久国产成人精品二区 | 69av精品久久久久久| 性少妇av在线| 日韩国内少妇激情av| 天天躁夜夜躁狠狠躁躁| 国产精品爽爽va在线观看网站 | 亚洲熟妇中文字幕五十中出 | 成人特级黄色片久久久久久久| 日本欧美视频一区| a级毛片在线看网站| 久久精品国产99精品国产亚洲性色 | 亚洲久久久国产精品| 麻豆av在线久日| 国产单亲对白刺激| 欧美乱色亚洲激情| 欧美av亚洲av综合av国产av| 中文字幕另类日韩欧美亚洲嫩草| 日本vs欧美在线观看视频| 免费观看精品视频网站| 亚洲三区欧美一区| 国产91精品成人一区二区三区| 满18在线观看网站| 亚洲男人的天堂狠狠| 欧美乱色亚洲激情| 国产不卡一卡二| 国产av精品麻豆| 国产国语露脸激情在线看| 夜夜躁狠狠躁天天躁| 变态另类成人亚洲欧美熟女 | 亚洲中文av在线| 国产精华一区二区三区| 黄色a级毛片大全视频| 午夜激情av网站| 国产又爽黄色视频| 久久亚洲真实| 天堂影院成人在线观看| 国产视频一区二区在线看| 久久精品国产亚洲av香蕉五月| 少妇裸体淫交视频免费看高清 | 欧美最黄视频在线播放免费 | 90打野战视频偷拍视频| av片东京热男人的天堂| 好看av亚洲va欧美ⅴa在| 自线自在国产av| 一二三四社区在线视频社区8| 亚洲一区二区三区欧美精品| 久久国产精品人妻蜜桃| 亚洲国产欧美日韩在线播放| 五月开心婷婷网| 男人操女人黄网站| 久久久久久久久中文| 亚洲国产欧美日韩在线播放| 欧美日韩中文字幕国产精品一区二区三区 | 亚洲精品一二三| 午夜福利在线观看吧| 少妇的丰满在线观看| 欧美一级毛片孕妇| 欧美 亚洲 国产 日韩一| 国产av在哪里看| 亚洲熟妇熟女久久| 亚洲欧美一区二区三区黑人| 国产av又大| 久99久视频精品免费| 最新美女视频免费是黄的| 水蜜桃什么品种好| 日韩 欧美 亚洲 中文字幕| 亚洲精品中文字幕一二三四区| 女人精品久久久久毛片| 99国产精品一区二区三区| 在线观看一区二区三区激情| 交换朋友夫妻互换小说| 成人18禁在线播放| 国产无遮挡羞羞视频在线观看| 黄片小视频在线播放| 丝袜人妻中文字幕| 高潮久久久久久久久久久不卡| 亚洲 欧美 日韩 在线 免费| 欧美日本中文国产一区发布| 桃色一区二区三区在线观看| 久久久久国产精品人妻aⅴ院| 99re在线观看精品视频| 午夜免费成人在线视频| 久久亚洲真实| 一级毛片女人18水好多| 国产成人系列免费观看| 欧美精品一区二区免费开放| 亚洲中文日韩欧美视频| 免费看a级黄色片| 日日干狠狠操夜夜爽| 日本三级黄在线观看| 国产精品亚洲一级av第二区| 91成年电影在线观看| 狂野欧美激情性xxxx| 欧美不卡视频在线免费观看 | 国产av一区在线观看免费| 999久久久精品免费观看国产| 国产三级黄色录像| 午夜久久久在线观看| 亚洲五月色婷婷综合| 99国产精品免费福利视频| 无人区码免费观看不卡| 午夜激情av网站| 亚洲成av片中文字幕在线观看| bbb黄色大片| 99国产精品一区二区三区| 在线永久观看黄色视频| 国产精品秋霞免费鲁丝片| 欧美日韩福利视频一区二区| 国产黄a三级三级三级人| 大陆偷拍与自拍| 国产黄色免费在线视频| 性色av乱码一区二区三区2| 法律面前人人平等表现在哪些方面| 欧美中文综合在线视频| 12—13女人毛片做爰片一| 女生性感内裤真人,穿戴方法视频| 老司机午夜十八禁免费视频| 亚洲精品成人av观看孕妇| 成年人免费黄色播放视频| 免费不卡黄色视频| 国产精品免费视频内射| 国产精品自产拍在线观看55亚洲| 久久午夜亚洲精品久久| 99香蕉大伊视频| 中出人妻视频一区二区| 正在播放国产对白刺激| 在线观看一区二区三区激情| 亚洲熟妇熟女久久| 中文字幕另类日韩欧美亚洲嫩草| 欧美激情高清一区二区三区| 99精品在免费线老司机午夜| 成人永久免费在线观看视频| 夜夜看夜夜爽夜夜摸 | 亚洲精品一区av在线观看| 亚洲片人在线观看| 不卡av一区二区三区| 又黄又粗又硬又大视频| 亚洲三区欧美一区| 精品一区二区三卡| 欧美日韩乱码在线| 亚洲av第一区精品v没综合| 欧美精品一区二区免费开放| 老司机午夜十八禁免费视频| 每晚都被弄得嗷嗷叫到高潮| 国产精品影院久久| 国产又色又爽无遮挡免费看| 国产成人精品在线电影| 亚洲一码二码三码区别大吗| 操美女的视频在线观看| 美女福利国产在线| 久久精品91蜜桃| 一区福利在线观看| 中文字幕另类日韩欧美亚洲嫩草| 日本vs欧美在线观看视频| 国产激情欧美一区二区| 国产精品免费视频内射| 国产一区在线观看成人免费| 黄色视频,在线免费观看| 欧美日韩视频精品一区| www.熟女人妻精品国产| 免费日韩欧美在线观看| 亚洲自拍偷在线| 国产av精品麻豆| 操出白浆在线播放| 一二三四在线观看免费中文在| 亚洲精品国产精品久久久不卡| 91麻豆av在线| 国产av在哪里看| 桃红色精品国产亚洲av| 一边摸一边抽搐一进一出视频| 成年人免费黄色播放视频| 高清av免费在线| 12—13女人毛片做爰片一| 大型av网站在线播放| av国产精品久久久久影院| 巨乳人妻的诱惑在线观看| 午夜精品在线福利| 又紧又爽又黄一区二区| 丝袜美腿诱惑在线| 91精品国产国语对白视频| 美女午夜性视频免费| 大型av网站在线播放| 欧美日韩乱码在线| 人人妻人人添人人爽欧美一区卜| 80岁老熟妇乱子伦牲交| 亚洲第一欧美日韩一区二区三区| 伊人久久大香线蕉亚洲五| 免费搜索国产男女视频| 老司机深夜福利视频在线观看| 亚洲久久久国产精品| 欧美成人免费av一区二区三区| 国产99白浆流出| 高清黄色对白视频在线免费看| 亚洲精品av麻豆狂野| 日韩欧美一区视频在线观看| 国产精品秋霞免费鲁丝片| 亚洲中文字幕日韩| 久久亚洲真实| 欧美日韩瑟瑟在线播放| 国产有黄有色有爽视频| 99国产精品99久久久久| 免费高清视频大片| 国产av一区在线观看免费| 午夜影院日韩av| 亚洲一卡2卡3卡4卡5卡精品中文| 亚洲人成网站在线播放欧美日韩| 最近最新中文字幕大全免费视频| 女人爽到高潮嗷嗷叫在线视频| 亚洲久久久国产精品| 亚洲男人的天堂狠狠| 日本五十路高清| 久久九九热精品免费| 一本大道久久a久久精品| 国产一区二区三区综合在线观看| 精品国产一区二区久久| 91精品国产国语对白视频| 99国产精品一区二区三区| 99精品久久久久人妻精品| 啦啦啦在线免费观看视频4| 动漫黄色视频在线观看| 成人av一区二区三区在线看| 一级a爱视频在线免费观看| 国产亚洲欧美98| 久久青草综合色| 日本黄色视频三级网站网址| 国产精品香港三级国产av潘金莲| 亚洲国产欧美一区二区综合| 在线播放国产精品三级| 亚洲一区二区三区色噜噜 | 日韩成人在线观看一区二区三区| 久久精品亚洲熟妇少妇任你| 亚洲国产精品999在线| 在线观看午夜福利视频| 亚洲欧美日韩高清在线视频| 成人精品一区二区免费| 黄色 视频免费看| 午夜免费成人在线视频| 国产成年人精品一区二区 | 国产成+人综合+亚洲专区| 久久国产精品男人的天堂亚洲| 天堂√8在线中文| 精品久久久久久电影网| 老司机亚洲免费影院| 午夜福利,免费看| 国产97色在线日韩免费| 欧美乱码精品一区二区三区| 中文亚洲av片在线观看爽| 亚洲熟妇中文字幕五十中出 | 99久久人妻综合| 国产精品自产拍在线观看55亚洲| 久久久国产一区二区| 看片在线看免费视频| 超碰97精品在线观看| 人成视频在线观看免费观看| 精品久久久久久久久久免费视频 | 一级片免费观看大全| 黄片播放在线免费| 欧美一区二区精品小视频在线| 高清黄色对白视频在线免费看| 亚洲精品一卡2卡三卡4卡5卡| 国产麻豆69| 亚洲情色 制服丝袜| 久久精品亚洲精品国产色婷小说| 成人av一区二区三区在线看| 国产黄a三级三级三级人| 久久天躁狠狠躁夜夜2o2o| 三级毛片av免费| 9191精品国产免费久久| 纯流量卡能插随身wifi吗| 国产成人精品无人区| 欧美丝袜亚洲另类 | 麻豆av在线久日| 国产精品野战在线观看 | 亚洲免费av在线视频| 9热在线视频观看99| 欧美日韩中文字幕国产精品一区二区三区 | 精品一品国产午夜福利视频| 亚洲九九香蕉| 麻豆国产av国片精品| 国产精品免费视频内射| 久久久久久久午夜电影 | 日本欧美视频一区| 免费高清在线观看日韩| 日本撒尿小便嘘嘘汇集6| 777久久人妻少妇嫩草av网站| 亚洲成人国产一区在线观看| 精品福利永久在线观看| 99国产精品99久久久久| 日韩免费av在线播放| 男女之事视频高清在线观看| 午夜老司机福利片| 黄色毛片三级朝国网站| 日本免费一区二区三区高清不卡 | 久久久国产成人免费| 午夜日韩欧美国产| 在线观看www视频免费| 美女大奶头视频| www.www免费av| 午夜福利影视在线免费观看| www.自偷自拍.com| 十八禁网站免费在线| 欧美一级毛片孕妇| 欧美日韩黄片免| 欧美在线一区亚洲| 久久久久国产一级毛片高清牌| 久久久久久人人人人人| 免费观看人在逋| 国产片内射在线| 久久香蕉精品热| 午夜福利免费观看在线| 精品无人区乱码1区二区| 欧美最黄视频在线播放免费 | 久久久久久久午夜电影 | 涩涩av久久男人的天堂| 成年人黄色毛片网站| 窝窝影院91人妻| 国产精品免费一区二区三区在线| 国产精品 国内视频| 美女福利国产在线| 久久人人精品亚洲av| 制服诱惑二区| 久久精品国产综合久久久| 精品电影一区二区在线| a级毛片在线看网站| 脱女人内裤的视频| 啦啦啦免费观看视频1| 热99re8久久精品国产| 女同久久另类99精品国产91| 老汉色av国产亚洲站长工具| 超色免费av| av国产精品久久久久影院| 欧美老熟妇乱子伦牲交| 成人国语在线视频| 老熟妇仑乱视频hdxx| 欧美在线一区亚洲| 成人18禁高潮啪啪吃奶动态图| 国产精品免费视频内射| 欧美老熟妇乱子伦牲交| 欧美人与性动交α欧美精品济南到| 嫩草影视91久久| 精品久久久久久久毛片微露脸| 多毛熟女@视频| 成年版毛片免费区| www.999成人在线观看| 视频区图区小说| 免费日韩欧美在线观看| 久久久国产欧美日韩av| 亚洲人成电影观看| netflix在线观看网站| 黄色成人免费大全| 免费在线观看完整版高清| 欧美丝袜亚洲另类 | 亚洲国产欧美网| 黄色女人牲交| 两性夫妻黄色片| 看免费av毛片| 欧美激情 高清一区二区三区| 免费久久久久久久精品成人欧美视频| 欧美不卡视频在线免费观看 | 久久久国产一区二区| 又紧又爽又黄一区二区| 日韩视频一区二区在线观看| 精品国内亚洲2022精品成人| 国产av一区二区精品久久| 校园春色视频在线观看| 久久人人精品亚洲av| 久9热在线精品视频| 一级a爱视频在线免费观看| 长腿黑丝高跟| 黄片播放在线免费| 精品一区二区三卡| 视频在线观看一区二区三区| 免费观看精品视频网站| 天天躁夜夜躁狠狠躁躁| 国产av精品麻豆| 久久草成人影院| 免费看十八禁软件| 国产精品av久久久久免费| 久久人妻av系列| 国产又爽黄色视频| 母亲3免费完整高清在线观看| 欧美人与性动交α欧美软件| 国产又色又爽无遮挡免费看| 两人在一起打扑克的视频| 动漫黄色视频在线观看| 亚洲七黄色美女视频| 黄色毛片三级朝国网站| 91麻豆精品激情在线观看国产 | 亚洲欧美精品综合一区二区三区| 久久人妻熟女aⅴ| 亚洲欧美一区二区三区久久| 亚洲成av片中文字幕在线观看| 久久香蕉激情| 成熟少妇高潮喷水视频| 很黄的视频免费| 19禁男女啪啪无遮挡网站| 制服人妻中文乱码| 少妇被粗大的猛进出69影院| 熟女少妇亚洲综合色aaa.| 亚洲国产精品sss在线观看 | 91在线观看av| 亚洲av电影在线进入| 免费一级毛片在线播放高清视频 | 69av精品久久久久久| 中文字幕高清在线视频| 99国产精品免费福利视频| 久久久久久久久免费视频了| 99re在线观看精品视频| 欧美成人免费av一区二区三区| 国产又爽黄色视频| 女人被狂操c到高潮| 波多野结衣高清无吗| 99热国产这里只有精品6| 纯流量卡能插随身wifi吗| 国产熟女午夜一区二区三区| 成人特级黄色片久久久久久久| av网站免费在线观看视频| 免费日韩欧美在线观看| 日本a在线网址| 日韩国内少妇激情av| 大型av网站在线播放| 两性午夜刺激爽爽歪歪视频在线观看 | 精品国产美女av久久久久小说| 一级片'在线观看视频| 一级a爱片免费观看的视频| 亚洲人成伊人成综合网2020| 激情视频va一区二区三区| a级毛片在线看网站| 国产乱人伦免费视频| 人成视频在线观看免费观看| 韩国av一区二区三区四区| 琪琪午夜伦伦电影理论片6080| 人人澡人人妻人| 国产欧美日韩一区二区三| 国内久久婷婷六月综合欲色啪| 少妇被粗大的猛进出69影院| 美女扒开内裤让男人捅视频| 久久久国产欧美日韩av| 性少妇av在线| 午夜免费成人在线视频| 日本wwww免费看| 亚洲精品在线观看二区| 国产精品秋霞免费鲁丝片| 大型黄色视频在线免费观看| 18禁黄网站禁片午夜丰满| 纯流量卡能插随身wifi吗| 亚洲人成电影免费在线| 悠悠久久av| 欧美人与性动交α欧美精品济南到| 亚洲精品国产区一区二| 99在线视频只有这里精品首页| 国产一区二区三区视频了| 如日韩欧美国产精品一区二区三区| 精品国产超薄肉色丝袜足j| 中文欧美无线码| 亚洲五月色婷婷综合| 成人国产一区最新在线观看| 在线观看免费午夜福利视频| 国产高清视频在线播放一区| 精品熟女少妇八av免费久了| 超碰97精品在线观看| 桃红色精品国产亚洲av| 黄网站色视频无遮挡免费观看| 国产av又大| 午夜精品国产一区二区电影| 在线观看免费午夜福利视频| 亚洲第一av免费看| 免费观看精品视频网站| 久久99一区二区三区| 国产无遮挡羞羞视频在线观看| 在线av久久热| 国产成年人精品一区二区 | 国产成人精品久久二区二区91| 欧美亚洲日本最大视频资源| 精品欧美一区二区三区在线| 天堂√8在线中文| 老司机亚洲免费影院| 后天国语完整版免费观看| 一级a爱片免费观看的视频| 黄色a级毛片大全视频| 免费观看人在逋| 精品一区二区三区视频在线观看免费 | 亚洲中文日韩欧美视频| av网站免费在线观看视频| 18禁观看日本| www.熟女人妻精品国产| 91成年电影在线观看| 黄色成人免费大全| aaaaa片日本免费| 国产免费av片在线观看野外av| 国产成人精品久久二区二区免费| 国产精品久久视频播放| 精品人妻1区二区| 制服人妻中文乱码| 中文字幕人妻丝袜制服| 老汉色∧v一级毛片| 精品久久蜜臀av无| 啦啦啦 在线观看视频| 亚洲午夜精品一区,二区,三区| 国产精品美女特级片免费视频播放器 | 99国产精品免费福利视频| 热99国产精品久久久久久7| 麻豆国产av国片精品| 一a级毛片在线观看| 久久 成人 亚洲| 亚洲国产欧美一区二区综合| 亚洲精品在线观看二区| 丰满迷人的少妇在线观看| 欧美激情高清一区二区三区| 妹子高潮喷水视频| 精品午夜福利视频在线观看一区| 国产三级黄色录像| 欧美精品亚洲一区二区| aaaaa片日本免费| avwww免费| 亚洲情色 制服丝袜| 久久久久久久午夜电影 | 黑丝袜美女国产一区| 亚洲久久久国产精品| 亚洲中文日韩欧美视频| 国内毛片毛片毛片毛片毛片| 老司机亚洲免费影院| 一级片免费观看大全| 成人特级黄色片久久久久久久| 欧美日韩一级在线毛片| 国产三级在线视频| 精品久久久久久成人av| 日韩欧美三级三区| 一级毛片精品| 香蕉丝袜av| 一二三四在线观看免费中文在| 久久午夜亚洲精品久久| 欧美+亚洲+日韩+国产| 成年女人毛片免费观看观看9| 日韩精品免费视频一区二区三区| 久久午夜综合久久蜜桃| 久久香蕉国产精品| 女人爽到高潮嗷嗷叫在线视频| 交换朋友夫妻互换小说| 精品一区二区三区视频在线观看免费 | 精品一区二区三区四区五区乱码| 搡老岳熟女国产| 搡老乐熟女国产| 亚洲av日韩精品久久久久久密| 欧美人与性动交α欧美软件| 久久精品91无色码中文字幕| 亚洲成人久久性| 女人被狂操c到高潮| 亚洲视频免费观看视频| 99国产精品99久久久久| 狠狠狠狠99中文字幕| 一边摸一边做爽爽视频免费| 中出人妻视频一区二区| 久久久国产精品麻豆| 丰满饥渴人妻一区二区三| 亚洲欧美精品综合久久99| 久久久久久大精品| 妹子高潮喷水视频| 日本三级黄在线观看| 黄色视频,在线免费观看| 每晚都被弄得嗷嗷叫到高潮| 国产片内射在线| 亚洲七黄色美女视频| 日韩欧美国产一区二区入口|